Psychopharmacology of aggression in children and adolescents with primary neuropsychiatric disorders: A review of current and potentially promising treatment options

Experimental and Clinical Psychopharmacology

Volumn 18, Issue 2, 2010, Pages 184-201

  Nevels, Robert M ^a   Dehon, Erin E ^a   Alexander, Katrina ^a   Gontkovsky, Samuel T ^b  

^a JACKSON STATE UNIVERSITY   (United States)

^b METHODIST REHABILITATION CENTER   (United States)

Author keywords

Aggression in children and adolescents; Disorders with comorbid aggression; Pediatric psychopharmacology; Treatment

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ARIPIPRAZOLE; ARMODAFINIL; ASENAPINE; ATOMOXETINE; CARBAMAZEPINE; CLONIDINE; DEPAKOTE ER; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; FANAPT; GUANFACINE; HALOPERIDOL; ILOPERIDONE; IMIPRAMINE; INTUNIV; LAMOTRIGINE; LISDEXAMFETAMINE; LITHIUM; METHYLPHENIDATE; MODAFINIL; NORTRIPTYLINE; OLANZAPINE; OXCARBAZEPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

ABDOMINAL PAIN; ACNE; ADOLESCENT; AGGRESSION; AKATHISIA; ANOREXIA; ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR MANIA; BLOOD PRESSURE; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHILD; CLINICAL TRIAL; COMORBIDITY; CONDUCT DISORDER; CONTROLLED RELEASE FORMULATION; DECREASED APPETITE; DEHYDRATION; DEPRESSION; DISRUPTIVE BEHAVIOR; DIZZINESS; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG MONITORING; DRUG OVERDOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEART MUSCLE CONDUCTION DISTURBANCE; HOSTILITY; HUMAN; HYPERLIPIDEMIA; HYPERPROLACTINEMIA; HYPOTHYROIDISM; INSOMNIA; INSULIN RESISTANCE; IRRITABILITY; KIDNEY FUNCTION; LEUKOCYTOSIS; MANIC DEPRESSIVE PSYCHOSIS; MENTAL DEFICIENCY; MIXED MANIA AND DEPRESSION; NARCOLEPSY; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; OFF LABEL DRUG USE; OPPOSITIONAL DEFIANT DISORDER; POLYDIPSIA; POLYURIA; PSYCHOPHARMACOLOGY; PSYCHOSIS; QT PROLONGATION; RHINITIS; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; STEVENS JOHNSON SYNDROME; THIRST; TREMOR; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; AGGRESSION; CHILD; CHILD, PRESCHOOL; DRUG COSTS; DRUG LABELING; FEMALE; GUIDELINES AS TOPIC; HUMANS; MALE; MENTAL DISORDERS; PSYCHOTROPIC DRUGS;

EID: 77952872259     PISSN: 10641297     EISSN: None     Source Type: Journal    
DOI: 10.1037/a0018059     Document Type: Article

References (94)

1. Abikoff H.B., Jensen P.S., Arnold L.E., Hoza B., Hechtman L., Pollack S., Wigal T. Observed classroom behavior of children with ADHD: Relationship to gender and comorbidity. Journal of Abnormal Psychology 2002, 30:349-359.
2. Althoff R.R., Rettew D.C., Hudziak J.J. Attention-deficit/hyperactivity disorder, oppositional defiant disorder, and conduct disorder. Psychiatric Annals 2003, 33:245-252.
3. Aman M.G. Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder. Seminars in Pediatric Neurology 2004, 11:225-228.
4. Arsten A.F. Fundamentals of attention-deficit/hyperactivity disorder: Circuits and pathways. Journal of Clinical Psychiatry 2006, 67(Suppl. 8):7-12.
5. Barkley R.A. Attention deficit hyperactivity disorders: A handbook for diagnosis and treatment 1998, Guilford Press, New York.
6. Barkley R.A. Issues in the diagnosis of attention-deficit/hyperactivity disorder in children. Brain and Development 2003, 25:77-83.
7. Barkley R.A., Benton C.M. Your defiant child: 8 steps to better behavior 1998, Guilford Press, New York, NY.
8. Benson B.A., Aman M.G. Disruptive behavior disorders in children with mental retardation. Handbook of disruptive behavior disorders 1999, 559-578. Plenum Press, New York, NY. H.C. Quay, A.E. Hogan (Eds.).
9. Biederman J., Krishnan S., Zhang Y., McGough J.J., Findling R.L. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clinical Therapeutics 2007, 29:450-463.
10. Biederman J., Mick E., Spencer T., Doyle R., Joshi G., Hammerness P., Wozniak J. An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. CNS Spectrums 2007, 12:683-689.
11. Biederman J., Monuteaux M.C., Spencer T., Wilens T.E., MacPhearson H.A., Faraone S.V. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: A naturalistic controlled 10-year follow-up study. American Journal of Psychiatry 2008, 165:597-603.
12. Biederman J., Swanson J.M., Wigal S.B., Kratochvil C.J., Boellner S.W., Earl C.Q., Greenhill J. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: Results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics 2005, 116:777-784.
13. Biederman J., Wilens T., Mick E., Spencer T., Faraone S.V. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 1999, 104. doi: 10.1542/peds.104.2.e20.
14. Breitenstein S.M., Hill C., Gross D. Understanding disruptive behavior problems in preschool children. Journal of Pediatric Nursing 2009, 24:3-12.
15. Burgess K.B., Rose-Krasnor L., Wojslawowicz J.C., Rubin K.H., Booth-LaForce C. Social information processing and coping strategies of shy/withdrawn and aggressive children: Does friendship matter?. Child Development 2006, 77:371-383.
16. Campbell M., Anderson L.T., Small A.M., Adams P., Gonzalez N.M., Ernst M. Naltrexone in autistic children: Behavioral symptoms and attentional learning. Journal of the American Academy of Child and Adolescent Psychiatry 1993, 32:1283-1291.
17. Campbell M., Small A.M., Green W.H., Jennings S.J., Perry R., Bennett W.G., Anderson L. Behavioral efficacy of haloperidol and lithium carbonate. A comparison in hospitalized aggressive children with conduct disorder. Archives of General Psychiatry 1984, 41:650-656.
18. Cohen I., Tsiouris J.A., Pfadt A. Effects of long-acting propranolol on agonistic and stereotyped behaviors in a man with pervasive developmental disorder and fragile-X syndrome: A double-blind, placebo controlled study. Journal of Clinical Psychopharmacology 1991, 11:398-399.
19. Conner D.E., Edwards G., Fletcher K.E., Baird J., Barkley R.A., Steingard R.J. Correlates of comorbid psychopathology in children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry 2003, 42:193-200.
20. Connor D.F., Fletcher K.E., Swanson J.M. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 1999, 38:1551-1559.
21. Connor D.F., Glatt S.J., Lopez I.D., Jackson D., Melloni R.H. Psychopharmacology and aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-Related behaviors in ADHD. Journal of the American Academy of Child and Adolescent Psychiatry 2002, 41:253-260.
22. Coryell W., Solomon D., Turvey C., Keller M., Leon A.C., Endicott J., Mueller T. The long-term course of rapid-cycling bipolar disorder. Archives of General Psychiatry 2003, 60:914-920.
23. Croonenberghs J., Fegert J.M., Findling R.L., Smedt G., Van Dongen S. Risperidone in children with disruptive behavior disorders and subaverage intelligence: A 1-year, open-label study of 504 patients. Journal of the American Academy of Child and Adolescent Psychiatry 2005, 44:64-72. the Risperidone Disruptive Behavior Study Group.
24. DeYoung C.G., Peterson J.B., Séguin J.R., Mejia J.M., Pihl R.O., Beitchman J.H., Palmour R.M. The dopamine D4 receptor gene and moderation of the association between externalizing behavior and IQ. Archives of General Psychiatry 2006, 63:1410-1416.
25. Efron D., Jarman F., Barker M. Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial. Pediatrics 1997, doi: 10.1542/peds.100.6.e6.
26. Erickson C.A., Posey D.J., Stigler K.A., Mullet J., Katsche A.R., McDougle C.J. A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology 2007, 191:141-147.
27. Exkorn K.S. The autism sourcebook: Everything you need to know about diagnosis, treatment, coping, and healing 2005, HarperCollins, New York, NY.
28. Faraone S.V., Biederman J., Roe C.M. Comparative efficacy of adderall and methylphenidate in attention-deficit/hyperactivity disorder: A meta-analysis. Journal of Clinical Psychopharmacology 2002, 22:468-473.
29. Findling R.L. Treatment of aggression in children. Primary care companion. Journal of Clinical Psychiatry 2003, 5(Suppl. 6):5-9.
30. Findling R.L. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: A review. Clinical Therapeutics 2008, 30:942-957.
31. Findling R.L., Aman M.G., Eerdekens M., Derivan A., Lyons B. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. American Journal of Psychiatry 2004, 161:677-684. the Risperidone Disruptive Behavior Study Group.
32. Findling R.L., McNamara N.K., Gracious B.L., Youngstrom E.A., Stansbrey R.J., Reed M.D., Calabrese J.R. Combination of lithium and divalproex sodium in pediatric bipolarity. Journal of the American Academy of Child and Adolescent Psychiatry 2003, 42:895-901.
33. Frazier J.A., McClellan J., Findling R.L., Vitiello B., Anderson R., Zablotsky B., Sikich L. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): Demographic and clinical characteristics. Journal of the American Academy of Child and Adolescent Psychiatry 2007, 46:979-988.
34. Fukuda T., Sugie H., Ito M., Sugie Y. Clinical evaluation of treatment with fluvoxamine, a selective serotonin reuptake inhibitor in children with autistic disorder. No To Hattatsu 2001, 33:314-318.
35. Gauthier Y. Infant mental health as we enter the third millennium: Can we prevent aggression?. Infant Mental Health Journal 2003, 24:296-308.
36. Geller B., Debello M.P. Bipolar disorder in childhood and early adolescence 2003, Guilford Press, New York, NY.
37. Golden C.J., Jackson M.L., Peterson-Rohne A., Gontkovsky S.T. Neuropsychological correlates of violence and aggression: A review of the clinical literature. Aggression and Violent Behavior 1996, 1:3-25.
38. Goldman L.S., Genel M., Bezman R.J., Slanetz P.J. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Journal of the American Medical Association 1998, 279:1100-1107.
39. Gontkovsky S.T. Neurobiological bases and neuropsychological correlates of aggression and violence. Psychology of aggression 2005, 101-116. Nova Science, Hauppauge, NY. J.P. Morgan (Ed.).
40. Guy W. Assessment manual for psychopharmacology-revised (DHEW Publ No ADM 76-338, pp. 218-222) 1976, U.S. Department of Health, Education, and Welfare, Rockville, MD.
41. Haber J.S. ADHD: The great misdiagnosis 2003, Taylor Trade, Lanham, MD.
42. Hagerman R.J. Medical follow-up and pharmacotherapy. Fragile X syndrome: Diagnosis, treatment, and research 1996, 283-331. Johns Hopkins University Press, Baltimore, MD. 2nd ed. R.J. Hagerman, A. Cronister (Eds.).
43. Hagerman R.J. Fragile X syndrome 1999, Oxford University Press, New York, NY.
44. Hagerman R.J., Fulton M.J., Leaman A., Riddle J., Hagerman K., Sobesky W. A survey of fluoxetine therapy in fragile X syndrome. Developmental Brain Dysfunction 1994, 7:155-164.
45. Hazell P.L., Stuart J.E. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. Journal of the American Academy of Child and Adolescent Psychiatry 2003, 42:886-894.
46. Hechtman L., Greenfield B. Long-term use of stimulants in children with attention hyperactivity disorder: Safety, efficacy and long-term outcome. Paediatric Drugs 2003, 5:787-794.
47. Ipser J., Stein D. Systematic review of pharmacotherapy of disruptive behavioral disorders in children and adolescents. Psychopharmacology 2007, 191:127-140.
48. Jensen P.S., Vitiello B., Leonard H., Laughren T.P. Design and methodology issues for clinical treatment trials in children and adolescents. Child and adolescent psychopharmacology: Expanding the research base. Psychopharmacology Bulletin 1994, 30:3-8.
49. Jepson B. Changing the course of autism: A scientific course for parents and physicians 2007, Sentient, Boulder, CO.
50. Julien R.M., Advokat C.D., Comaty J.E. A primer of drug action: A comprehensive guide to the actions, uses, and side effects of psychoactive drugs 2008, Worth, New York, NY. 11th ed.
51. Kelsey D.K., Sumner C.R., Casat C.D., Coury D.L., Quintana H., Saylor K.E., Allen A.J. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebo-controlled trial. Pediatrics 2004, 114:e1-8.
52. King B.H., Hollander E., Sikich L., McCracken J.T., Scahill L., Bregman J.D., Ritz L. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: Citalopram ineffective in children with autism. Archives of General Psychiatry 2009, 66:583-590.
53. Kolmen B.K., Feldman H.M., Handen B.L., Janosky J.E. Naltrexone in young autistic children: A double-blind, placebo-controlled crossover study. Journal of the American Academy of Child and Adolescent Psychiatry 1995, 34:223-231.
54. Kowatch R.A., Fristad M., Birmaher B., Wagner K., Findling R., Hellander M. Treatment guidelines for children and adolescents with bipolar disorder: Child psychiatric workgroup on bipolar disorder. Journal of the American Academy of Child and Adolescent Psychiatry 2005, 44:213-235.
55. Kowatch R.A., Suppes T., Carmody T.J., Bucci J.P., Hume J.H., Kromelis M., Rush A.J. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. Journal of the American Academy of Child and Adolescent Psychiatry 2000, 39:713-720.
56. Kranzler H., Roofeh D., Gerbino-Rosen G., Dombrowski C., McMeniman M., DeThomas C., Kumra S. Clozapine: Its impact on aggressive behavior among children and adolescents with schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry 2005, 44:55-63.
57. Manuzza S., Klein R.G., Truong N.L., Moulton J.L., Roizen E.R., Howell K.H., Castellanos F.X. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: Prospective follow-up into adulthood. American Journal of Psychiatry 2008, 165:604-609.
58. McClintock K., Hall S., Oliver C. Risk markers associated with challenging behaviours in people with intellectual disabilities: A meta-analytic study. Journal of Intellectual Disability Research 2003, 47:405-416.
59. McDougle C.J., Naylor S.T., Cohen D.J., Volkmar F.R., Heninger G.R., Price L.H. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry 1996, 53:1001-1008.
60. Mick E., Biederman J., Pandina G., Faraone S.V. A preliminary meta analysis of the Child Behavior Checklist in pediatric bipolar disorder. Biological Psychiatry 2003, 53:1021-1027.
61. Molina B.S.G., Hinshaw S.P., Swanson J.M., Arnold L.E., Vitiello B., Jensen P.S. The MTA at 8 years: Prospective follow-up of children treated for combined type ADHD in the multisite study. Journal of the American Academy of Child and Adolescent Psychiatry 2009, the MTA Cooperative Group, Advance online publication. doi: 10.1097/CHI.0b013e31819c23d0.
62. Pandina G.J., Aman M.G., Findling R.L. Risperidone in the management of disruptive behavioral disorders. Journal of Child and Adolescent Psychopharmacology 2006, 16:379-392.
63. Pandina G.J., Bossie C.A., Youssef E., Zhu Y., Dunbar F. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders 2007, 37:367-373.
64. Pappadopulos E., Woolston S., Chait A., Perkins M., Connor D.F., Jensen P.S. Pharmacotherapy of aggression in children and adolescents: Efficacy and effect size. Journal of the Canadian Academy of Child and Adolescent Psychiatry 2006, 15:27-39.
65. Pavuluri M.N., Henry D.B., Carbray J.A., Sampson G., Naylor M.W., Janicak P.G. Open-label prospective trial of risperidone in combination with lithium and divalproex sodium in pediatric mania. Journal of Affective Disorders 2004, 82:103-111.
66. Pliszka S.R., Carlson C.L., Swanson J.M. ADHD with comorbid disorders: Clinical assessment and management 2001, Guilford Press, New York, NY.
67. Polzer J., Bangs M.E., Zhang S.Y., Dellva M.A., Tauscher-Wisniewski S., Acharya N., Wilens T.E. Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD. Biological Psychiatry 2007, 61:713-719.
68. Posey D.J., Stigler K.A., Erickson C.A., McDougle C.J. Antipsychotics in the treatment of autism. Journal of Clinical Investigations 2008, 118:6-14.
69. Preston J., O'Neal J.H., Talaga M.C. Child and adolescent clinical psychopharmacology made simple 2006, New Harbinger, Oakland, CA.
70. Preston J., O'Neal J.H., Talaga M.C. Handbook of clinical psychopharmacology for therapists 2008, New Harbinger, Oakland, CA. 5th ed.
71. Psychopharmacological Drugs Advisory Committee and the Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee. (February 2, 2004). Retrieved from http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm161696.htm.
72. Ruginvo T.A., Janvier Y.M. Aripiprazole in children and adolescents: Clinical experience. Journal of Child Neurology 2005, 20:603-610.
73. Sachs G.S., Baldassano C.F., Truman C.J., Guille C. Comorbidity of attention deficit hyperactivity disorder with early- and late-onset bipolar disorder. American Journal of Psychiatry 2000, 157:466-468.
74. Sallee F., McGough J., Wigal T., Donahue J., Lyne A., Biederman J. Guanfacine extended release in children and adolescents with ADHD: A placebo-controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry 2009, 48:1-11.
75. Santosh P.J., Baird G., Pityaratstian N., Tavare E., Gringras P. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: A retrospective and prospective effectiveness study. Child Care Health Development 2006, 32:575-583.
76. Schneck C.D., Miklowitz D.J., Miyahara S., Araga M., Wisniewski S., Gyulai L., Sachs G.S. The prospective course of rapid-cycling bipolar disorder: Findings from the STEP-BD. American Journal of Psychiatry 2008, 165:370-377.
77. Singh N.N., Lancioni G.E., Winton A.S.W., Fisher B.C., Wahler R.G., McAleavey K., Sabaawi M. Mindful parenting decreases aggression, noncompliance, and self-injury in children with autism. Journal of Emotional and Behavioral Disorders 2006, 14:169-177.
78. Stahl S.M. Essential psychopharmacology: The prescriber's guide 2005, Cambridge University Press, Cambridge, England.
79. Stahl S.M. Stahl's essential psychopharmacology: Neuroscientific basis and practical applications 2008, Cambridge University Press, Cambridge, England. 3rd ed.
80. Staller J.A. Psychopharmacologic treatment of aggressive preschoolers: A chart review. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2007, 31:131-135.
81. Sukhodolsky D.G., Vitulano L.A., Carroll D.H., McGuire J., Leckman J.F., Schahill L. Randomized trial of anger control training for adolescents with Tourette's syndrome and disruptive behavior. Journal of the American Academy of Child and Adolescent Psychiatry 2009, 48:413-420.
82. Swanson J.W., Swartz M.S., Van Dorn R.A., Volavka J., Monahan J., Stroup T.S., Lieberman J.A. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. British Journal of Psychiatry 2008, 193:37-43.
83. Tandon R., Carpenter W.T., Davis J.M. First- and second-generation antipsychotics: Learning from CUtLASS and CATIE. Archives of General Psychiatry 2007, 64:977-988.
84. Toren P., Ratner S., Laor N., Weizman A. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug Safety 2004, 27:1135-1156.
85. Tremblay R.E., Nagin D.S., Seguin J.R., Zoccolillo M., Zelazo P.D., Boivin M., Japel C. Physical aggression during early childhood: Trajectories and predictors. Pediatrics 2004, 114:43-50.
86. Suicidality in children and adolescents being treated with antidepressant medications 2004, U.S. Food and Drug Administration, Retrieved from http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm161679.htm.
87. Worsening depression and suicidality in patients being treated with antidepressants 2004, U.S. Food and Drug Administration, Retrieved from http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm161696.htm.
88. U.S. Food and Drug Administration. (2004, February). Meeting of the Psychopharmacological Drugs Advisory Committee and the Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee.
89. Vedantam S. FDA links antidepressants, youth suicide risk. The Washington Post 2004, February 3, A01.
90. Vetter V.L., Elia J., Erickson C., Berger S., Blum N., Uzark K., Webb C.L. Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs. A scientific statement from the American Heart Association Council on cardiovascular disease in the young congenital cardiac defects committee and the Council on Cardiovascular Nursing. Circulation 2008, 117:2407-2423.
91. Wada A., Yokoo H., Yanagita T., Kobayashi H. Lithium: Potential therapeutics against acute brain injuries and chronic neurodegenerative diseases. Journal of Pharmacological Sciences 2005, 99:307-321.
92. Washburn J.J., McMahon S.D., King C.A., Reinecke M.A., Silver C. Narcissistic features in young adolescents: Relations to aggression and internalizing symptoms. Journal of Youth and Adolescence 2004, 33:247-260.
93. Werner N.E., Nixon C.L. Normative beliefs and relational aggression: An investigation of the cognitive bases of adolescent aggressive behavior. Journal of Youth and Adolescence 2005, 34:229-243.
94. Yan J. Short, intensive ADHD treatments are not long-term panacea. Psychiatric News 2009, May 15, 44:1-20.